Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
NKTX Nkarta
- 2.010
- -0.100-4.74%
Close Apr 28 16:00 ET
- 2.110
- +0.100+4.98%
Post 17:58 ET
142.62MMarket Cap-1.26P/E (TTM)
2.160High1.980Low656.91KVolume2.100Open2.110Pre Close1.33MTurnover1.34%Turnover RatioLossP/E (Static)70.96MShares8.23052wk High0.35P/B98.26MFloat Cap1.31052wk Low--Dividend TTM48.88MShs Float79.160Historical High--Div YieldTTM8.53%Amplitude1.280Historical Low2.027Avg Price1Lot Size
About Nkarta Company
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Company Profile
SymbolNKTX
Company NameNkarta
Listing DateJul 10, 2020
Issue Price18.00
Founded2005
CEOMr. Paul J. Hastings
MarketNASDAQ
Employees157
Fiscal Year Ends12-31
Address1150 Veterans Boulevard
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-925-407-1049
Websitehttp://www.nkartatx.com
Company Executives
- Name
- Position
- Salary
- Paul J. Hastings
- Chief Executive Officer and Director
- 3.99M
- Dr. Nadir Mahmood, PhD
- Chief Financial Officer and Principal Accounting Officer
- 3.34M
- Dr. David R. Shook, M.D.
- Chief Medical Officer and Head, Research and Development
- 1.90M
- Dr. Ali Behbahani, M.B.A.,M.D.
- Chairman of the Board
- 204.88K
- Leone D Patterson
- Independent Director
- 174.10K
- Angela Thedinga
- Independent Director
- 171.55K
- Dr. Zachary Scheiner, PhD
- Independent Director
- 164.83K
- Dr. Simeon J. George, M.B.A.,M.D.
- Independent Director
- 164.24K
- Dr. Michael Dybbs, PhD
- Independent Director
- 175.10K
- Dr. George Vratsanos, M.D.
- Independent Director
- 268.38K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
